Literature DB >> 22542949

Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.

Erika M Kwon1, Sarah K Holt, Rong Fu, Suzanne Kolb, Gabrielle Williams, Janet L Stanford, Elaine A Ostrander.   

Abstract

BACKGROUND: Prostate cancer (PC) is the most frequently diagnosed solid tumor in U.S. men. Genome-wide association studies (GWAS) have identified over 40 risk-associated single nucleotide polymorphisms (SNPs), including variants in androgen pathway genes (e.g., KLK3 and AR). Androgens are important in PC and genes involved in this pathway are therefore candidates for conferring susceptibility to PC.
METHODS: In this hypothesis-testing study, we evaluated PC risk in association with SNPs in 22 candidate genes involved in androgen metabolism or interactions with the androgen receptor (AR). A total of 187 SNPs were genotyped in 1458 cases and 1351 age-matched controls from a population-based study. PC risk was estimated using adjusted unconditional logistic regression and multinomial regression models.
RESULTS: Single SNP analyses showed evidence (p < 0.05) for associations with 14 SNPs in 9 genes: NKX3.1, HSD17B3, AKR1C3, SULT2A1, CYP17A1, KLK3, JAK2, NCOA4 and STAT3. The most significant result was observed for rs2253502 in HSD17B3 (odds ratio, OR = 0.57, 95% CI: 0.39-0.84). In addition, five SNPs in four genes (CYP17A1, HSD17B4, NCOA4, and SULT2A1) were associated with more aggressive disease (p < 0.01).
CONCLUSIONS: Our results replicate previously reported associations for SNPs in CYP17A1, HSD17B3, ARK1C3, NKX3.1, NCOA4 and KLK3. In addition, novel associations were observed for SNPs in JAK2, HSD17B4, and SULT2A1. These results will require replication in larger studies. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22542949      PMCID: PMC3392409          DOI: 10.1016/j.canep.2012.04.002

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  49 in total

1.  Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer.

Authors:  Joke Beuten; Jonathan A L Gelfond; Jennifer L Franke; Korri S Weldon; Analisa C Crandall; Teresa L Johnson-Pais; Ian M Thompson; Robin J Leach
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

2.  MENDELIAN PROPORTIONS IN A MIXED POPULATION.

Authors:  G H Hardy
Journal:  Science       Date:  1908-07-10       Impact factor: 47.728

3.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

4.  Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.

Authors:  Lei Gu; Xian-Hua Zhu; Tapio Visakorpi; Kalle Alanen; Tuomas Mirtti; Tina Bocker Edmonston; Marja T Nevalainen
Journal:  Anal Cell Pathol (Amst)       Date:  2010       Impact factor: 2.916

5.  Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men.

Authors:  Teresa W Wilborn; Nicholas P Lang; Michelle Smith; Sreelatha Meleth; Charles N Falany
Journal:  J Steroid Biochem Mol Biol       Date:  2006-04-17       Impact factor: 4.292

6.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

7.  Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer.

Authors:  Abraham Morgentaler
Journal:  J Sex Med       Date:  2008-06-10       Impact factor: 3.802

8.  Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men.

Authors:  Katia Margiotti; Eugene Kim; C Leigh Pearce; Enrico Spera; Giuseppe Novelli; Juergen K V Reichardt
Journal:  Prostate       Date:  2002-09-15       Impact factor: 4.104

9.  Variation in KLK genes, prostate-specific antigen and risk of prostate cancer.

Authors:  Jiyoung Ahn; Sonja I Berndt; Sholom Wacholder; Peter Kraft; Adam S Kibel; Meredith Yeager; Demetrius Albanes; Edward Giovannucci; Meir J Stampfer; Jarmo Virtamo; Michael J Thun; Heather Spencer Feigelson; Geraldine Cancel-Tassin; Olivier Cussenot; Gilles Thomas; David J Hunter; Joseph F Fraumeni; Robert N Hoover; Stephen J Chanock; Richard B Hayes
Journal:  Nat Genet       Date:  2008-09       Impact factor: 38.330

10.  Stat3 enhances transactivation of steroid hormone receptors.

Authors:  Fernando De Miguel; Soo Ok Lee; Sergio A Onate; Allen C Gao
Journal:  Nucl Recept       Date:  2003-06-13
View more
  20 in total

1.  STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.

Authors:  Ling Zhao; Qingyuan Zhang; Xin Luan; Xu Huang; Shu Zhao; Hong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches.

Authors:  Seyed Hamid Aghaee-Bakhtiari; Ehsan Arefian; Mahmood Naderi; Farshid Noorbakhsh; Vahideh Nodouzi; Mojgan Asgari; Pezhman Fard-Esfahani; Reza Mahdian; Masoud Soleimani
Journal:  Tumour Biol       Date:  2015-01-22

3.  Polymorphisms in immune mediators associate with risk of cervical cancer.

Authors:  Zhengyan Zhang; Samantha Fye; Ingrid B Borecki; Janet S Rader
Journal:  Gynecol Oncol       Date:  2014-08-12       Impact factor: 5.482

4.  Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis C-related liver disease in males.

Authors:  Donna L White; Yanhong Liu; Jose Garcia; Hashem B El-Serag; Li Jiao; Spiridon Tsavachidis; Luis M Franco; Ju-Seog Lee; Shahriar Tavakoli-Tabasi; David Moore; Radoslav Goldman; Jill Kuzniarek; David J Ramsey; Fasiha Kanwal; Marco Marcelli
Journal:  Int J Mol Epidemiol Genet       Date:  2014-10-22

5.  The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms.

Authors:  Zhen Lu; Robert C Bast
Journal:  Cell Adh Migr       Date:  2013-01-28       Impact factor: 3.405

6.  RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.

Authors:  Monica Logan; Philip D Anderson; Shahrazad T Saab; Omar Hameed; Sarki A Abdulkadir
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

7.  Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.

Authors:  Emanuela Taioli; Vestra Sears; Alexis Watson; Rafael E Flores-Obando; Maria D Jackson; Flora A Ukoli; Ilce M de Syllos Cólus; Pedro Fernandez; Norma McFarlane-Anderson; Elaine A Ostrander; Iara S Rodrigues; Janet L Stanford; Jack A Taylor; Marshall Tulloch-Reid; Camille C R Ragin
Journal:  Prostate       Date:  2012-11-05       Impact factor: 4.104

8.  FAM64A is an androgen receptor-regulated feedback tumor promoter in prostate cancer.

Authors:  Yingchen Zhou; Longhua Ou; Jinming Xu; Haichao Yuan; Junhua Luo; Bentao Shi; Xianxin Li; Shangqi Yang; Yan Wang
Journal:  Cell Death Dis       Date:  2021-07-02       Impact factor: 8.469

9.  Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer.

Authors:  Jenny J Schulze; Helena Karypidis; Lena Ekström
Journal:  Front Pharmacol       Date:  2012-08-06       Impact factor: 5.810

10.  Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.

Authors:  Henrique B da Silva; Eduardo P Amaral; Eduardo L Nolasco; Nathalia C de Victo; Rodrigo Atique; Carina C Jank; Valesca Anschau; Luiz F Zerbini; Ricardo G Correa
Journal:  Prostate Cancer       Date:  2013-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.